Primary B cell engineering for therapeutic research

Evan Kleinboehl; Kanut Laoharawee; Branden S. Moriarity

doi:10.1016/j.molmed.2022.03.007

Primary B cell engineering for therapeutic research

Evan Kleinboehl, Kanut Laoharawee, Branden S. Moriarity

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	528-529
Number of pages	2
Journal	Trends in Molecular Medicine
Volume	28
Issue number	6
DOIs	https://doi.org/10.1016/j.molmed.2022.03.007
State	Published - Jun 2022

Bibliographical note

Funding Information:
Figures were created with biorender.com, B.S.M. is a founder and equity holder in Bespoke Biotherapeutics LLC. The remaining authors have no interests to declare.

Keywords

B cells
gene editing
immune cell engineering
protein replacement therapy

Publisher link

10.1016/j.molmed.2022.03.007

Find It

Find It at U of M Libraries

Cite this

@article{7e0f905402ca465cb42cdaa2b9a05b51,

title = "Primary B cell engineering for therapeutic research",

keywords = "B cells, gene editing, immune cell engineering, protein replacement therapy",

author = "Evan Kleinboehl and Kanut Laoharawee and Moriarity, {Branden S.}",

note = "Funding Information: Figures were created with biorender.com, B.S.M. is a founder and equity holder in Bespoke Biotherapeutics LLC. The remaining authors have no interests to declare.",

year = "2022",

month = jun,

doi = "10.1016/j.molmed.2022.03.007",

language = "English (US)",

volume = "28",

pages = "528--529",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Primary B cell engineering for therapeutic research

AU - Kleinboehl, Evan

AU - Laoharawee, Kanut

AU - Moriarity, Branden S.

N1 - Funding Information: Figures were created with biorender.com, B.S.M. is a founder and equity holder in Bespoke Biotherapeutics LLC. The remaining authors have no interests to declare.

PY - 2022/6

Y1 - 2022/6

KW - B cells

KW - gene editing

KW - immune cell engineering

KW - protein replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=85128163186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128163186&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2022.03.007

DO - 10.1016/j.molmed.2022.03.007

M3 - Short survey

C2 - 35430120

AN - SCOPUS:85128163186

SN - 1471-4914

VL - 28

SP - 528

EP - 529

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 6

ER -

Primary B cell engineering for therapeutic research

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Cite this